Sanofi (EPA: SAN)
France
· Delayed Price · Currency is EUR | Market Cap | 126.83B |
| Revenue (ttm) | 47.08B |
| Net Income (ttm) | 4.22B |
| Shares Out | 1.25B |
| EPS (ttm) | 3.36 |
| PE Ratio | 30.11 |
| Forward PE | 12.37 |
| Dividend | 3.76 (3.72%) |
| Ex-Dividend Date | May 13, 2024 |
| Volume | 1,965,387 |
| Open | 101.70 |
| Previous Close | 101.44 |
| Day's Range | 101.08 - 102.18 |
| 52-Week Range | 80.60 - 104.32 |
| Beta | 0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 25, 2024 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, TTE's revenue was $218.95 billion, a decrease of -16.85% compared to the previous year's $263.31 billion. Earnings were $21.38 billion, an increase of 4.18%.
Financial StatementsNews
Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
Sanofi: Better Buying Opportunities May Present Themselves In 2024
Sanofi: Better Buying Opportunities May Present Themselves In 2024
Empowering Marketing Teams With Claudine Patel, CMO of Sanofi
Welcome to another special episode of the Marketing Vanguard podcast. Today, ADWEEK chief experience officer Jenny Rooney welcomes Claudine Patel, Sanofi's chief marketing officer for consumer healthc...
Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry
In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices. In this article...
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry o...
France's PAI Partners engages UAEs ADIA for Sanofi consumer health bid - report
The Abu Dhabi fund is among the most active investors in private equity-led transactions
PAI Said to Rope in Sovereign Funds for Sanofi Consumer Unit Bid
Buyout firm PAI Partners is seeking to rope in two of the world’s largest sovereign wealth funds to back its offer for French drugmaker Sanofi SA’s consumer health division, according to people famili...
South Africa: Sanofi commits to affordable insulin pens for diabetic patients
It's estimated that more than 31,000 people in South Africa live with Type 1 diabetes and require full insulin replacement therapy, with multiple daily injections
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
Earlier this month, the FDA approved ARS Pharmaceuticals Inc’s (NASDAQ: SPRY) neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life...
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp...
Three Biotech Stocks to Buy for the "Golden Age of Medicine"
A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed "a Golden Age of Medicine" is here.
Emcure Pharma Q1 net up 8%
Emcure Pharmaceuticals reported a consolidated net profit increase of 8% in Q1FY25, with revenue from operations rising by 17%. The company's domestic business saw significant growth, led by a distrib...
Profits climb 82pc to 308m as revenue and staff numbers rise at health giant Sanofis Waterford subsidiary
Pre-tax profits at the main Irish arm of biopharma giant Sanofi last year increased by 82pc to 308.29m.
In-Depth Analysis: Merck & Co Versus Competitors In Pharmaceuticals Industry
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma giant Sanofi.
Beiersdorf’s Axel Adida on Global Commerce Shifts
On this episode of the Brave Commerce podcast, hosts Rachel Tipograph and Sarah Hofstetter sit down with Axel Adida, chief digital officer at German skincare and hygiene giant Beiersdorf, to discuss t...
Sanofi makes $30M equity investment in MeiraGTx
MeiraGTx (MGTX) shares dropped 3% premarket as the genetic medicine company priced a $50M stock offering led by Sanofi (SNY) and others.
Sanofi makes $30M equity investment in MeiraGTx
MeiraGTx (MGTX) shares dropped 3% premarket as the genetic medicine company priced a $50M stock offering led by Sanofi (SNY) and others.
Novavax Lags on Q2 Earnings & Sales, Cuts '24 Outlook
Novavax (NASDAQ: NVAX) posted earnings per share of 99 cents in second-quarter 2024, missing the Zacks Consensus Estimate of $1.82. However, earnings rose 71% year over year. Revenues in the quarter ...
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
On Thursday, Novavax Inc (NASDAQ: NVAX) reported second-quarter 2024 sales of $415 million, compared to $424 million a year, missing the consensus of $458.6 million . Second quarter 2024 licensing, r...
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
Sanofi to invest 1.3 bln euros in new insulin plant in Frankfurt
French drugmaker Sanofi will invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt, where it makes insulin brand Lantus, the company said on T...